Maebashi, Japan

Kazuo Okano

This inventor holds 1 USPTO granted patent. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 1985.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuo Okano. Retrieved from https://idiyas.com/inventor/kazuo-okano-cnpq9il0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuo Okano: Innovator in Antibiotic Development

Introduction

Kazuo Okano is a notable inventor based in Maebashi, Japan. He is recognized for his contributions to the field of antibiotics, particularly through his innovative work on antibiotic SF-2288. His research has significant implications for antimicrobial treatments.

Latest Patents

Kazuo Okano holds a patent for antibiotic SF-2288 and its preparation method. This novel antibiotic is produced by the fermentation of an actinomycete belonging to the genus Actinomadura in a nutrient medium. Based on its physico-chemical and biological properties, antibiotic SF-2288 exhibits excellent antimicrobial activity against both Gram-positive and Gram-negative microorganisms, as well as antiviral activity.

Career Highlights

Kazuo Okano has made substantial contributions to the pharmaceutical industry through his work at Meiji Seika Kaisha, Ltd. His research and development efforts have focused on creating effective antibiotic solutions that address various microbial infections.

Collaborations

Some of his notable coworkers include Yasumitsu Kondo and Takashi Shomura, who have collaborated with him on various projects related to antibiotic development.

Conclusion

Kazuo Okano's innovative work in the field of antibiotics, particularly with antibiotic SF-2288, showcases his commitment to advancing medical science. His contributions have the potential to improve treatment options for infections caused by resistant microorganisms.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…